Novo Nordisk A/S (NYSE:NVO) is one of the best healthcare stocks under $50 to invest in. On February 5, BofA adjusted the price target on Novo Nordisk A/S (NYSE:NVO) to DKK 350 from DKK 400, reiterating a Neutral rating and lowering its EPS forecasts 7%-10% on the company’s weak 2026 guidance.
The same day, Novo Nordisk A/S (NYSE:NVO) issued a statement about the announcement by Hims & Hers that it would begin offering compounded copies of the Wegovy pill at an introductory price of $49 per month. Novo Nordisk A/S (NYSE:NVO) called the action by Hims & Hers an “illegal mass compounding” posing considerable risk to patient safety. It added that it would take regulatory and legal action to safeguard its patients, its intellectual property, and the integrity of the US gold-standard drug approval framework.
Novo Nordisk A/S (NYSE:NVO) further stated that it is the sole manufacturer of the FDA-approved Wegovy® pill formulated with SNAC technology, capable of facilitating semaglutide absorption through oral administration. The pill is available in all doses, in full supply, nationwide in the United States, and the compounded semaglutide is not approved by the FDA. The company added that it may contain untested doses, impurities, and unnecessary additives.
Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.
While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
